Table 3.
Comparisons of postprandial plasma glucose change from baseline in different treatment groups
| No. studies | No. participants (active agents vs PBO) | WMD from baseline | 95% CI | P‐value | |
|---|---|---|---|---|---|
| PPG change from baseline (mmol/L) | |||||
| DPP‐4i/INS | 2 | 626/470 | −1.65 | −2.34, −0.96 | <0.01 |
| AGI/INS | 3 | 208/207 | −1.76 | −4.19, 0.66 | 0.15 |
| GLP‐1RA/INS | 3 | 705/547 | −2.87 | −8.98, 3.23 | 0.36 |
| SGLT‐2i/INS | 2 | 146/83 | −2.62 | −2.86, −2.37 | <0.01 |
AGI, alpha‐glucosidase inhibitors; CI, confidence interval; DPP‐4i, dipeptidyl peptidase‐4 inhibitor; GLP‐1RA, glucagon‐like peptide‐1 receptor agonist; HbA1c, glycated hemoglobin; INS, insulin; PBO, placebo; PPG, postprandial plasma glucose; SGLT‐2i, sodium–glucose cotransporter 2 inhibitor; WMD, weighted mean difference.